Keros Therapeutics (KROS) EPS (Basic) Growth (1y) (2020 - 2026)
Powered by 
Analysis
Keros Therapeutics (KROS) EPS (Basic) Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.69 Bn | 192.70 Bn | 7.24 Bn | 65.24% |
| 2 | Gilead Sciences | 179.87 Bn | 176.70 Bn | 6.22 Bn | -636.10% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 7.74% |
| 4 | Regeneron Pharmaceuticals | 81.70 Bn | 73.71 Bn | 3.93 Bn | -4.72% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 87.85% |
| 6 | Moderna | 54.28 Bn | 49.14 Bn | 52.00 Mn | 7.59% |
| 7 | Alnylam Pharmaceuticals | 33.02 Bn | 29.71 Bn | 992.69 Mn | 322.67% |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | -84.77% |
| 9 | Roivant Sciences | 29.27 Bn | 29.27 Bn | 1.16 Mn | - |
| 10 | Keros Therapeutics | 221.17 Mn | -36.44 Mn | - | -91.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -91.84% |
| Dec 31, 2025 | 48.73% |
| Sep 30, 2025 | 87.28% |
| Jun 30, 2025 | 39.71% |
| Mar 31, 2025 | 402.95% |
| Dec 31, 2024 | 10.04% |
| Sep 30, 2024 | -5.97% |
| Jun 30, 2024 | 1.06% |
| Mar 31, 2024 | 4.27% |
| Dec 31, 2023 | -16.07% |
| Sep 30, 2023 | -44.48% |
| Jun 30, 2023 | -11.77% |
| Mar 31, 2023 | -25.20% |
| Dec 31, 2022 | -295.86% |
| Sep 30, 2022 | -5.91% |
| Jun 30, 2022 | -69.11% |
| Mar 31, 2022 | -47.41% |
| Dec 31, 2021 | 52.28% |
| Sep 30, 2021 | -45.64% |
| Jun 30, 2021 | -7.76% |